Portal de Periódicos da CAPES

Squamous cell carcinoma antigen (SCCA) is up-regulated during Barrett’s carcinogenesis and predicts esophageal adenocarcinoma resistance to neoadjuvant chemotherapy

2016; Impact Journals LLC; Volume: 8; Issue: 15 Linguagem: Inglês

10.18632/oncotarget.14108

1949-2553

Matteo Fassan, Stefano Realdon, Luca Vianello, Santina Quarta, Alberto Ruol, Carlo Castoro, Marco Scarpa, Giovanni Zaninotto, Vincenza Guzzardo, Vanna Chiarion‐Sileni, Patrizia Pontisso, Massimo Rugge,

Pancreatic and Hepatic Oncology Research

// Matteo Fassan 1 , Stefano Realdon 2 , Luca Vianello 1 , Santina Quarta 3 , Alberto Ruol 4 , Carlo Castoro 5 , Marco Scarpa 5 , Giovanni Zaninotto 6 , Vincenza Guzzardo 1 , Vanna Chiarion Sileni 7 , Patrizia Pontisso 3 , Massimo Rugge 1, 8 1 Department of Medicine (DIMED), Surgical Pathology Unit, University of Padua, Padua, Italy 2 Gastroenterology Unit, Istituto Oncologico Veneto, IOV-IRCCS, Padua, Italy 3 Department of Medicine (DIMED), 5th Medical Clinic, University of Padua, Padua, Italy 4 Department of Surgical, Oncological and Gastroenterological Sciences (DiSCOG), 3rd Surgical Clinic, University of Padua, Padua, Italy 5 Esophageal and Digestive Tract Surgical Unit, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy 6 Imperial College London, Department of Surgery and Cancer, Division of Surgery, London, UK 7 Melanoma & Esophageal Oncology Unit, Istituto Oncologico Veneto, IOV-IRCCS, Padua, Italy 8 Veneto Tumour Registry, Veneto Region, Padua, Italy Correspondence to: Patrizia Pontisso, email: patrizia@unipd.it Keywords: SCCA, esophageal adenocarcinoma, Barrett's carcinogenesis, preneoplastic lesions Received: July 29, 2016 Accepted: November 22, 2016 Published: December 22, 2016 ABSTRACT Squamous Cell Carcinoma Antigen (SCCA) is consistently overexpressed in many different solid tumors, and has been associated with both tumor aggressiveness and chemoresistance. No data, however, is currently available on SCCA expression during esophageal Barrett's carcinogenesis, nor on SCCA expression's role on esophageal adenocarcinoma chemoresistance. The SCCA immunohistochemical expression was assessed in a series of 100 biopsy samples covering the whole histological spectrum of Barrett's oncogenesis. Squamous native mucosa was characterized by a moderate to strong cytoplasmic and nuclear SCCA expression in suprabasal, medium, and superficial layers. On the other hand, almost half of the considered lesions did not express SCCA; the other half featured weak to moderate SCCA expression. The relationship between SCCA protein expression and tumor response to neoadjuvant chemotherapy was assessed in 90 esophageal adenocarcinoma specimens (40 biopsy and 50 surgery specimens), stratified according to Mandard tumor regression grade. As observed in other settings, the presence of SCCA expression clustered in the group of tumors characterized by a lower responsiveness to neoadjuvant treatments. The present results suggest an involvement of SCCA in a subset of Barrett-related tumors, and prompt to consider the SCCA-protein expression as response-predictive marker of neoadjuvant therapy in esophageal adenocarcinomas.